Lapadula G - Search Results

1

Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.

Torti C, Costarelli S, De Silvestri A, Quiros-Roldan E, Lapadula G, Cologni G, Paraninfo G, Castelnuovo F, Puoti M, Carosi G; BHCC Study Group. Torti C, et al. Among authors: lapadula g. Drug Saf. 2007;30(12):1161-9. doi: 10.2165/00002018-200730120-00008. Drug Saf. 2007. PMID: 18035868

2

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.

Torti C, Lapadula G, Casari S, Puoti M, Nelson M, Quiros-Roldan E, Bella D, Pastore G, Ladisa N, Minoli L, Sotgiu G, Mazzotta F, Lo Caputo S, Di Perri G, Filice G, Tinelli C, Carosi G; EPOKA-MASTER Study Group. Torti C, et al. Among authors: lapadula g. BMC Infect Dis. 2005 Jul 14;5:58. doi: 10.1186/1471-2334-5-58. BMC Infect Dis. 2005. PMID: 16018804 Free PMC article.

3

Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.

Torti C, Uccelli MC, Quiros-Roldan E, Gargiulo F, Tirelli V, Lapadula G, Regazzi M, Pierotti P, Tinelli C, De Luca A, Patroni A, Manca N, Carosi G. Torti C, et al. Among authors: lapadula g. J Clin Virol. 2006 Apr;35(4):414-9. doi: 10.1016/j.jcv.2005.10.001. Epub 2005 Nov 8. J Clin Virol. 2006. PMID: 16280255 Clinical Trial.

4

Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort.

Torti C, Lapadula G, Puoti M, Casari S, Uccelli MC, Cristini G, Bella D, Pastore G, Ladisa N, Minoli L, Sotgiu G, Caputo SL, Bonora S, Carosi G. Torti C, et al. Among authors: lapadula g. J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):180-5. doi: 10.1097/01.qai.0000192005.08153.a3. J Acquir Immune Defic Syndr. 2006. PMID: 16394850

5

Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART.

Uccelli MC, Torti C, Lapadula G, Labate L, Cologni G, Tirelli V, Moretti F, Costarelli S, Quiros-Roldan E, Carosi G. Uccelli MC, et al. Among authors: lapadula g. Ann Nutr Metab. 2006;50(3):247-52. doi: 10.1159/000091682. Epub 2006 Feb 23. Ann Nutr Metab. 2006. PMID: 16508252

6

Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy.

Lapadula G, Torti C, Paraninfo G, Castelnuovo F, Uccelli MC, Costarelli S, Ladisa N, Maserati R, Di Pietro M, De Silvestri A, Tinelli C, Puoti M, Carosi G; EPOKa-A Study Group of the MASTER Cohort. Lapadula G, et al. Antivir Ther. 2006;11(4):521-7. Antivir Ther. 2006. PMID: 16856626 Clinical Trial.

7

Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients.

Torti C, Lapadula G, Uccelli MC, Quiros-Roldan E, Regazzi M, Ladisa N, Micheli V, Orani A, Patroni A, Caputo SL, Tirelli V, Di Giambenedetto S, Cologni G, Costarelli S, Gargiulo F, Manca N, Carosi G; RADAR Study Group of MASTER Cohort. Torti C, et al. Among authors: lapadula g. Int J Antimicrob Agents. 2007 Feb;29(2):185-90. doi: 10.1016/j.ijantimicag.2006.08.015. Epub 2006 Oct 2. Int J Antimicrob Agents. 2007. PMID: 17011754

8

Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy.

Quiros-Roldan E, Torti C, Lapadula G, Ladisa N, Micheli V, Patroni A, Cusato M, Pierotti P, Tirelli V, Uccelli MC, Di Giambenedetto S, Castelnuovo F, Gargiulo F, Manca N, Carosi G; RADAR-Master Study Group. Quiros-Roldan E, et al. Among authors: lapadula g. AIDS Patient Care STDS. 2007 Feb;21(2):92-9. doi: 10.1089/apc.2005.0037. AIDS Patient Care STDS. 2007. PMID: 17328658 Clinical Trial.

9

CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.

Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G; Italian MASTER Cohort. Torti C, et al. Among authors: lapadula g. J Antimicrob Chemother. 2007 Jun;59(6):1141-7. doi: 10.1093/jac/dkm100. Epub 2007 Apr 13. J Antimicrob Chemother. 2007. PMID: 17434879

10

Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report.

Lapadula G, Izzo I, Costarelli S, Cologni G, Bercich L, Casari S, Gambarotti M, Torti C. Lapadula G, et al. J Med Case Rep. 2007 May 8;1:19. doi: 10.1186/1752-1947-1-19. J Med Case Rep. 2007. PMID: 17488516 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

409 results

Search Page

Filters